#Reporter Gene Assay Market Size

[anujmrfr]

Reporter Gene Assay Market Size, Growth Outlook 2035

Reporter Gene Assay Market Size was valued at USD 2.35 billion in 2023. The industry is projected to grow from USD 2.55 billion in 2024 to USD 5.11 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.07% during the forecast period (2024 - 2032).

Market Overview

The Reporter Gene Assay Market is growing significantly due to its crucial role in gene expression analysis, drug discovery, and biotechnology research. Reporter gene assays are widely used to monitor cellular events such as transcriptional activity, protein interactions, and signal transduction. These assays are integral in biopharmaceutical development and screening of potential drug candidates.

Market Size and Share

Reporter Gene Assay Market Size was valued at USD 2.35 billion in 2023. The industry is projected to grow from USD 2.55 billion in 2024 to USD 5.11 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.07% during the forecast period (2024 - 2032). The global market for reporter gene assays is expanding rapidly, with pharmaceutical and biotechnology companies being the primary end-users. The increasing demand for high-throughput screening (HTS) technologies and the adoption of bioluminescence-based assays are fueling market growth. North America holds the largest market share due to advanced research infrastructure, while Asia-Pacific is witnessing rapid growth due to increasing investments in genetic research.

Growth Drivers

Rising Demand for Drug Discovery: Reporter gene assays are extensively used in preclinical and clinical research for drug efficacy evaluation.

Advancements in Cell-Based Assays: The integration of fluorescence and luminescence-based detection methods is improving assay sensitivity.

Growing Focus on Personalized Medicine: The adoption of reporter gene technology in gene therapy and biomarker research is expanding applications.

Expanding Biopharmaceutical Industry: The growing number of biologic drugs and cell-based therapies is increasing the demand for reporter gene assays.

Challenges and Restraints

High Costs of Advanced Assay Kits: The pricing of cell-based assays can be a barrier for smaller research labs.

Stringent Regulatory Approvals: Compliance requirements for gene expression assays can slow market expansion.

Technical Limitations: Variability in gene expression results and interference in signal detection pose challenges.

Regional Analysis

North America: Leading the market due to strong R&D funding, presence of biotech firms, and extensive use of gene expression assays in drug research.

Europe: Growing adoption of cell-based assays in biopharmaceutical production and clinical research.

Asia-Pacific: Emerging as a key market due to increased investment in biotech research, expansion of contract research organizations (CROs), and government funding in genomics projects.

Segmental Analysis

The market is segmented based on:

Product Type:

Luciferase Assays

Fluorescent Protein Assays

β-Galactosidase Assays

Secreted Alkaline Phosphatase (SEAP) Assays

Application:

Drug Discovery

Gene Expression Analysis

Signal Transduction Studies

Cancer Research

End-User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations (CROs)

Key Market Players

Takara Bio

Sartorius AG

BioRad Laboratories

QIAGEN

Roche

Enzo Life Sciences

Recent Developments

Advancements in CRISPR-based reporter assays for precise gene function analysis.

Growing use of luminescent assays for real-time monitoring of gene expression.

Partnerships between biotech firms and pharmaceutical companies for high-throughput screening solutions.

For more information, please visit us at @marketresearchfuture.

[sometimespurvi]

Global HLA Typing Market: Growth Trends, Technologies, and Future Outlook

Market Overview

The global HLA typing market has experienced significant growth over the years, with an estimated market size of $33.4 billion in 2023. Projections indicate a remarkable expansion to $562.97 million by 2031, growing at a CAGR of 36.4% from 2024 to 2031. This rapid growth is fueled by increasing organ transplantation procedures, advancements in genetic testing, and the rising prevalence of autoimmune diseases.

Browse More : https://www.statsandresearch.com/report/40445-global-hla-typing-market/

Understanding HLA Typing

HLA typing is a laboratory test used to identify specific human leukocyte antigen (HLA) markers on an individual's cells. These markers are crucial for immune system function, helping distinguish self from non-self. The process is essential in organ transplantation to reduce the risk of rejection, as well as in autoimmune disease diagnosis and research. Accurate HLA typing ensures compatibility in transplantation, leading to improved patient outcomes.

Get a free sample copy : https://www.statsandresearch.com/request-sample/40445-global-hla-typing-market

Market Segmentation

By Geography

The HLA typing market is analyzed across multiple regions, including:

North America (United States, Canada)

Asia-Pacific (China, Japan, India, Korea, ASEAN)

Europe (Germany, France, UK, Italy, Spain, CIS)

Middle East and Africa

South America (Brazil and other key nations) Each region exhibits unique market dynamics, with North America leading in adoption due to advanced healthcare infrastructure and research capabilities.

By Technology

HLA typing employs various technological approaches, broadly classified into:

Molecular Assays:

Polymerase Chain Reaction (PCR): Identifies specific HLA alleles using amplification techniques.

Sequence-Specific Oligonucleotide (SSO) Probes: Detects genetic variations in HLA genes.

Sequence-Specific Primer (SSP) Typing: Provides high-precision allele identification.

Real-Time PCR (qPCR): Offers quantitative analysis of allele expression.

Next-Generation Sequencing (NGS): Enables high-resolution typing by sequencing entire HLA genes.

Sanger Sequencing: Provides accurate validation for identified HLA genes.

Non-Molecular Assays:

Serological Assays: Detect HLA antigens through antibody-based techniques.

Mixed Lymphocyte Culture (MLC): Assesses immune compatibility by analyzing lymphocyte responses.

By Product & Service

HLA typing solutions are categorized into:

Instruments: Sequencers, PCR systems

Reagents & Consumables: Oligonucleotide probes, antibodies, assay kits

Software & Services: HLA typing software, data analysis services, consulting services

By Application

Transplantation:

Solid Organ Transplantation (Kidney, Liver, Heart)

Hematopoietic Stem Cell Transplantation (HSCT)

Disease Diagnosis:

Cancer

Autoimmune Diseases

Infectious Diseases

Research:

Immunogenetics

Population Genetics

By End User

Hospitals & Transplant Centers

Academic & Research Institutes

Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Enquiry : https://www.statsandresearch.com/enquire-before/40445-global-hla-typing-market

Key Market Players

The competitive landscape comprises leading biotechnology and diagnostics companies, including:

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories Inc.

Qiagen N.V.

Omixon Inc.

GenDx

Illumina Inc.

TBG Diagnostics Limited

Dickinson and Company

Takara Bio Inc.

F. Hoffman-La Roche Limited

Pacific Biosciences

Future Outlook

The HLA typing market is poised for continued expansion, driven by technological advancements, increased healthcare investments, and the growing demand for precision medicine. As the industry evolves, improved sequencing techniques and AI-driven data analysis will further enhance HLA typing accuracy and efficiency, solidifying its role in transplantation and disease management.

For customized insights or sample pages of this report, feel free to reach out!

Find Out Top Trending Reports Here :

Global Sex Reassignment Surgery Market

Global Enzyme Engineering Market

Global Neuroelectronic Devices Market

Global Vitamin K2 Market Insights 

Global Defibrillator Market Insights

[global-research-report]

Comprehensive Study on the Multiplex Assay Market

The global multiplex assay market size is expected to reach USD 3.87 billion by 2030, registering a CAGR of 14.77% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of infectious diseases is boosting the usage of multiplex assays in clinical trials. For instance, according to the American Cancer Society in 2021, 1.9 million cancer cases were reported along with 6,08,570 deaths in the United States. Multiplex assay aids in the diagnosis of cancer and reduces unnecessary invasive producers. Thus, growing chronic diseases can boost the necessity of these assays and is anticipated to fuel market growth. The increasing adoption of personalized medicine in recent years is another key factor driving the growth.

Personalized medicine is a precise medicine for an individual patient to attain improved treatment options based on the body type and disease risk. These assays ensure to be highly beneficial for the comprehensive diagnosis of personalized medicines. For instance, according to an article published in the MDPI journal in 2020, multiplex immunoassay provides a complete picture of the disease and pathways involved in Rheumatoid Arthritis (RA) and simultaneously analyzes multiple proteins that can yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine. During the COVID-19 pandemic, multiplex testing continued to be an essential tool for healthcare professionals in effectively managing the spread of COVID-19. In addition, recently, several private companies have also developed novel versions of multiplex assays.

For instance, in Sept 2020, LabCorp launched an at-home collection version for diagnosis of influenza A/B, COVID-19, and respiratory syncytial virus single-panel tests. Furthermore, the advantages of multiplex assay over singleplex and traditional assay can boost the industry growth in coming years. Several benefits offered by these automated tests include microsampling capability, numerous arrays measured in a single trial, quicker results, high operational efficiency, easy operations, and reduced labor expenses. Thus, the industry has witnessed incremental growth in 2021 and is anticipated to have a similar trend during the forecast period. Moreover, increasing validation of the biomarkers in molecular & protein diagnostics and the rising need for high-throughput and automated systems are expected to create lucrative opportunities during the forecast period.

Multiple biomarker analysis has a wide range of applications in the area of infectious diseases, neurodegenerative diseases, autoimmune diseases, and cancer. Numerous biomarkers are being discovered, and there is a high possibility of the development of novel diagnostics. For instance, Cipla launched RT Direct multiplex PCR kit that delivers quicker results for COVID-19. Such developments can increase the market penetration of multiplex assay during the forecast period. The technological advancements and automation in the multiplex assay, improve the efficiency and speed of delivering accurate results. For instance, in July 2020, Luminex provided xMAP the INTELLIFLEX system to discover novel applications, including the exclusive ability to detect multiple antibodies in a single serology test.

In May 2022, Vela Diagnostics launched a highly automated multiplex PCR-based test for detecting antimicrobial resistance genes and UTI pathogens. Hence novel technological developments can fuel the industry growth in the near future. However, the high cost of equipment can restrict the usage of multiplex assays by researchers and manufacturers in mid and low-income countries. Also, the quality control standards and regulations are more stringent for multiplex assay compared to singlex assay, which can impede the industry growth during the forecast period.

Multiplex Assay Market Report Highlights

By product, the consumables segment held the dominant share in 2022. This is due to the recurring purchase of consumables along with the rise in the number of diagnostic tests

The protein multiplex assay type segment dominated the industry in 2022 due to the increasing focus on proteomics studies for biomarker research and clinical diagnostics

The flow cytometry technology segment held a larger share in 2022. Constant efforts by various companies to launch novel and technological advanced flow cytometer is the key factor driving the segment

The research & development application segment held the largest share in 2022 due to the utilization of these assays in clinical & preclinical stages to evaluate toxicity, immunotherapy success, and drug response biomarkers

The pharmaceutical & biotechnology companies end-user segment led the industry in 2022 due to a rise in pharma & biotech partnerships and collaborations to increase the multiplexing capabilities

North America dominated the global industry in 2022 due to the growing R&D activities as a result of the increasing prevalence of chronic diseases

Asia Pacific is estimated to register the fastest CAGRfrom 2022 to 2030 due to the rising number of hospitals in emerging countries, the developing R&D sector, and the high demand for healthcare infrastructure in the region

Multiplex Assay Market Segmentation

Grand View Research has segmented the global multiplex assay market based on product, type, technology, application, end-user, and region:

Multiplex Assay Product Outlook (Revenue, USD Million, 2018 - 2030)

Consumables

Instruments

Software

Multiplex Assay Type Outlook (Revenue, USD Million, 2018 - 2030)

Protein Multiplex Assays

Planar Protein Assays

Bead-based Protein Assays

Nucleic Acid Multiplex Assays

Planar Protein Assays

Bead-based Protein Assays

Cell-based Multiplex Assays

Multiplex Assay Technology Outlook (Revenue, USD Million, 2018 - 2030)

Flow Cytometry

Fluorescence Detection

Luminescence

Multiplex Real-time PCR

Other Technologies

Multiplex Assay Application Outlook (Revenue, USD Million, 2018 - 2030)

Research & Development

Drug Discovery & Development

Biomarker Discovery & Validation

Clinical Diagnostics

Infectious Diseases

Cancer

Cardiovascular Diseases

Autoimmune Diseases

Nervous System Disorders

Metabolism & Endocrinology Disorders

Other Diseases

Multiplex Assay End-user Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical & Biotechnology Companies

Hospitals & Diagnostic laboratories

Research & Academic Institutes

Other End-users

Multiplex Assay Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Asia Pacific

Japan

China

India

South Korea

Australia

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Order a free sample PDF of the Multiplex Assay Market Intelligence Study, published by Grand View Research.

[surbhijamdade]

Liquid Handling System Market Report: A Comprehensive Analysis of the Growing Demand for Efficient Liquid Handling Solutions

Liquid Handling System Market Report: A Comprehensive Analysis of the Growing Demand for Efficient Liquid Handling Solutions

Market Definition and Latest Trends

The liquid handling system market refers to the industry that provides equipment and solutions for handling liquids in various laboratory, research, and industrial settings. The market includes manual, semi-automated, and automated liquid handling systems, which are used for pipetting, dispensing, and other liquid handling tasks. The latest trends in the market include the increasing adoption of automated liquid handling systems, the growing demand for high-throughput liquid handling solutions, and the rising importance of precision and accuracy in liquid handling applications.

Market Size and Growth Prospects

According to a recent report by Straits Research, the global liquid handling system market size was valued at USD 4.59 Billion in 2024 and is projected to reach from USD 4.81 Billion in 2025 to USD 7.00 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2025–2033).

Requset a Sample Report of Liquid Handling System Market

Market Segmentation

The liquid handling system market is segmented based on type, product, application, and end-user.

By Type

Manual Liquid Handling: Manual liquid handling systems are used for low-throughput applications and require manual operation.

Automated Liquid Handling: Automated liquid handling systems are used for high-throughput applications and offer high precision and accuracy.

Semi-automated Liquid Handling: Semi-automated liquid handling systems offer a balance between manual and automated liquid handling systems.

By Product

Automated Workstations: Automated workstations are integrated systems that offer automated liquid handling, sample preparation, and other laboratory tasks.

Pipettes: Pipettes are handheld instruments used for measuring and transferring liquids.

Dispensers: Dispensers are instruments used for dispensing liquids in precise volumes.

Burettes: Burettes are instruments used for measuring the volume of liquids.

Other Products: Other products include liquid handling accessories, consumables, and software.

By Application

Drug Discovery: Liquid handling systems are used in drug discovery applications, such as high-throughput screening and lead optimization.

Cancer and Genomics Research: Liquid handling systems are used in cancer and genomics research applications, such as next-generation sequencing and gene expression analysis.

Clinical Diagnostics: Liquid handling systems are used in clinical diagnostics applications, such as molecular diagnostics and immunoassays.

Other Applications: Other applications include food and beverage testing, environmental monitoring, and industrial research and development.

By End User

Pharmaceutical and Biotechnology Industry: The pharmaceutical and biotechnology industry is the largest end-user of liquid handling systems, using them for drug discovery, development, and manufacturing.

Contract Research Organization: Contract research organizations use liquid handling systems for research and development services, such as assay development and testing.

Academic Institutes: Academic institutes use liquid handling systems for research and education purposes, such as teaching and research laboratories.

Other End Users: Other end users include government laboratories, environmental monitoring agencies, and food and beverage companies.

Browse Full Report and TOC of Liquid Handling System Market

Key Opportunity

The increasing adoption of automated liquid handling systems is a key opportunity for the market. Automated liquid handling systems offer high precision, accuracy, and throughput, making them ideal for high-throughput applications such as drug discovery and genomics research.

Key Players

Some of the key players operating in the liquid handling system market include:

Agilent Technologies

Bio-Rad Laboratories Inc.

Corning Incorporated

Eppendorf AG

Hamilton Company

PerkinElmer Inc.

Promega Corporation

Thermo Fisher Scientific Inc.

Danaher Corporation

Tecan Trading AG

10x Genomics

These companies offer a range of liquid handling systems, including automated workstations, pipettes, dispensers, and burettes. They also provide software and services for liquid handling applications.

Buy Liquid Handling System Market Report here!

About Straits Research

Straits Research is a top provider of business intelligence, specializing in research, analytics, and advisory services, with a focus on delivering in-depth insights through comprehensive reports.

Contact Us

Email: sales@straitsresearch.com

Address: 825 3rd Avenue, New York, NY, USA, 10022

Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)

[jayanthitbrc]

Global Reporter Gene Assay Market Analysis 2024: Size Forecast and Growth Prospects

The reporter gene assay global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Reporter Gene Assay Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The reporter gene assay market size has grown strongly in recent years. It will grow from $5.88 billion in 2023 to $6.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising demand for cell-based assays, rise in genomics research, increased drug discovery and development research, rising need for personalized treatment, and demand for early diagnosis.

The reporter gene assay market size is expected to see strong growth in the next few years. It will grow to $9.03 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the rising prevalence of chronic genetic disorders, growing demand for personalized medicine, growing use of molecular imaging systems, expansion of gene therapy portfolios, and government initiatives. Major trends in the forecast period include technological advancements in gene therapy, advancements in molecular biology, demand for advanced molecular diagnostic tools, shift towards 3d cell culture models, and strategic partnerships

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/reporter-gene-assay-global-market-report

Scope Of Reporter Gene Assay Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Reporter Gene Assay Market Overview

Market Drivers - The increasing drug discovery and development research is expected to propel the growth of the reporter gene assay market. Drug discovery and development research refers to the systematic process within the medical, biotechnology, and pharmacology fields that leads to identifying, creating, and introducing new medications to the market. The increasing drug discovery and development research is due to advancements in proteomics, high-throughput screening, genomics, and novel medications' successful development and approval. Reporter gene assays serve as valuable tools in discovery and development research, enabling researchers to gain insights into gene regulation, identify potential drug targets, screen compound libraries, and evaluate the efficacy and safety of candidate drugs. For instance, in April 2024, according to the Office for National Statistics, a UK-based government department, the UK government's net expenditure on research and development (R&D) rose to £15.5 billion ($19.7 billion) in 2022 from £14.0 billion ($17.8 billion) in 2021, an increase of 10.5%. Therefore, increasing drug discovery and development research is driving the growth of the reporter gene assay market.

Market Trends - Major companies operating in the reporter gene assay market are focusing on developing innovative solutions, such as ultrasensitive multiplexed digital PCR assays, to strengthen their position in the market. Ultrasensitive multiplexed digital PCR (dPCR) assays precisely detect and quantify nucleic acids by partitioning the sample into thousands or millions of individual reactions, each containing minute amounts of target DNA or RNA molecules. For instance, in April 2024, Bio-Rad Laboratories Inc., a US-based life science research company, launched the ddPLEX ESR1 Mutation Detection Kit, the first ultrasensitive multiplexed digital PCR assay. This new ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection excels in sensitivity, detecting minute mutations in complex samples for early and precise disease monitoring. Its multiplexing feature enables simultaneous detection of multiple mutations, simplifying testing. This groundbreaking assay promises to revolutionize breast cancer research and personalized treatment strategies.

The reporter gene assay market covered in this report is segmented –

1) By Product: Assay Kits, Reagents 2) By Application: Promoter Structural And Functional Analysis, Cell Signaling Pathways, Protein Interaction, Clinical And Gene Regulation 3) By End-User: Biotechnology And Pharmaceutical Companies, Research And Academic Institutes, Hospital And Diagnostic Laboratories, Contract Research Organizations

Get an inside scoop of the reporter gene assay market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16526&type=smp

Regional Insights - North America was the largest region in the reporter gene assay market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the reporter gene assay market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the reporter gene assay market are <b>Roche Diagnostics, Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD Biosciences), GE Healthcare, Lonza Group, Agilent Technologies, Sartorius AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GenScript Biotech Corporation, Abcam plc, Promega Corporation, Promega Corporation, Takara Bio Inc., New England Biolabs (NEB), OriGene Technologies Inc., Cell Signaling Technology Inc., SABiosciences, Enzo Biochem Inc., InvivoGen, Biotium Inc., Enzo Life Sciences Inc., BioAssay Systems, Indigo Biosciences Inc.</b>

Table of Contents 1. Executive Summary 2. Reporter Gene Assay Market Report Structure 3. Reporter Gene Assay Market Trends And Strategies 4. Reporter Gene Assay Market – Macro Economic Scenario 5. Reporter Gene Assay Market Size And Growth ….. 27. Reporter Gene Assay Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[farmacuticals]

Exploring Growth Opportunities in the Reporter Gene Assay Market: Trends and Future Outlook

A Reporter Gene Assay is a powerful tool used in molecular biology to study gene expression, regulation, and cellular signaling. This technique involves inserting a reporter gene, such as luciferase, GFP (green fluorescent protein), or β-galactosidase, into the genome of a cell or organism. The expression of this reporter gene is then measured to indicate the activity of the gene or pathway under study. This assay is widely used in both basic and applied research, as it provides quantifiable data on the effects of various treatments, environmental conditions, or genetic modifications on gene expression.

The Reporter Gene Assay Market Size was projected as 16.19 (USD Billion) in 2022 based on MRFR analysis. It is anticipated that the market for reporter gene assays would increase from 17.46 billion USD in 2023 to 34.5 billion USD in 2032. Throughout the forecast period (2024–2032), the Reporter Gene Assay Market is anticipated to develop at a CAGR of approximately 7.86%.

The market size of Reporter Gene Assays is substantial, driven by high demand in various research fields, including drug development, cancer research, and genetics. These assays are instrumental in high-throughput screening processes and play a critical role in pharmaceutical and biotech industries, academic research institutions, and clinical laboratories. The broad applicability and versatility of Reporter Gene Assays continue to propel their market growth, and experts predict that this trend will continue in the coming years due to ongoing advancements in gene-editing technologies and the rising importance of precision medicine.

Reporter Gene Assay Market Share and Analysis

In recent years, the Reporter Gene Assay market share has seen considerable growth, primarily due to the increasing adoption of advanced gene expression technologies in research and diagnostics. The market is segmented by type (luminescent, fluorescent, and colorimetric assays), application (drug discovery, disease research, gene therapy, and others), and end-user (pharmaceutical companies, academic research institutions, and diagnostic labs). Among these, the luminescent Reporter Gene Assay segment holds a significant market share due to its high sensitivity and suitability for high-throughput screening.

Key players in the Reporter Gene Assay market, including Promega Corporation, Thermo Fisher Scientific, and Merck KGaA, are investing heavily in R&D to introduce innovative products and expand their product portfolios. North America leads the market in terms of revenue, followed closely by Europe, while the Asia-Pacific region is expected to witness the fastest growth due to increased investment in biotech research and development. In-depth Reporter Gene Assay analysis indicates that the market’s competitive landscape is shaped by collaborations, partnerships, and acquisitions aimed at expanding the technological capabilities of major companies and providing comprehensive solutions to end-users.

Reporter Gene Assay Trends

Several trends are shaping the Reporter Gene Assay market. First, there is an increased focus on the development of non-toxic, highly sensitive reporter genes to facilitate real-time and in vivo imaging, which is crucial for studying gene expression in living organisms. Second, the rising demand for Reporter Gene Assays in personalized medicine and targeted therapies is driving market growth. These assays allow researchers to determine the therapeutic efficacy of drugs on a molecular level, which is essential in creating personalized treatment plans. Third, technological advancements, such as automation and miniaturization, are making these assays more accessible and efficient, further boosting their popularity in laboratories worldwide. Additionally, the emergence of CRISPR-based reporter gene editing is revolutionizing Reporter Gene Assay applications, providing higher precision and efficiency in genetic research.

Reasons to Buy Reporter Gene Assay Reports

Comprehensive Market Insights: Reporter Gene Assay reports offer in-depth insights into market trends, competitive landscapes, and emerging applications, making them invaluable resources for researchers and industry professionals.

Data-Driven Analysis: These reports provide accurate data on market size, share, growth forecasts, and detailed analysis of market segments and regional performance.

Technological Developments: Reporter Gene Assay reports highlight recent technological advancements and innovations, allowing users to stay ahead in this rapidly evolving field.

Investment Opportunities: The reports identify investment opportunities and strategic recommendations for businesses aiming to expand their footprint in the Reporter Gene Assay market.

Regulatory Insights: With the growing importance of regulatory standards in gene research, the reports provide essential regulatory information relevant to the Reporter Gene Assay market, ensuring compliance for stakeholders.

Recent Developments

Recent developments in the Reporter Gene Assay market reflect ongoing innovation and growth. For instance, there have been significant advancements in bioluminescent and fluorescent reporter genes that enhance assay sensitivity and reduce background noise, making it easier for researchers to obtain accurate results. Major companies are also introducing next-generation Reporter Gene Assay kits designed for high-throughput screening and automated systems, improving assay efficiency and throughput. Additionally, collaborations between industry players and academic institutions have led to the development of new assay formats tailored for emerging fields like synthetic biology and precision oncology.

Overall, the Reporter Gene Assay market is expected to continue expanding as researchers increasingly rely on these assays for detailed gene expression analysis. These recent developments and trends make Reporter Gene Assay technology an indispensable tool for advancing molecular biology research and personalized medicine applications.

Related reports:

weight loss drugs market

portable ultrasound market

3d printed drugs market

[harshnews]

Reporter Gene Assay Market Size, Share, Trends, Growth Opportunities, Key Drivers and Competitive Outlook

"Reporter Gene Assay Market – Industry Trends and Forecast to 2029

Global Reporter Gene Assay Market, By Product (Assay Kits and Reagents), Application (Promoter Structural and Functional Analysis, Cell Signaling Pathways, Protein Interaction, In Vitro Studies, Clinical and Gene Regulation), Application (Gene Regulation, Protein Interaction, Cell Signalling Pathways), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, CROs) – Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **By Product Type**: The reporter gene assay market can be segmented by product type into assay kits, reagents, cell lines, and instruments. Assay kits are essential in reporter gene assays as they contain all the necessary components for the analysis. Reagents are crucial for the preparation and execution of the assays, providing the necessary chemicals and substrates. Cell lines are another key segment as they play a vital role in gene expression studies. Instruments segment includes luminometers, microplate readers, and other equipment required for detection and analysis.

- **By Application**: The market for reporter gene assays can be segmented by application into drug discovery and development, gene regulation studies, protein-protein interaction, and promoter analysis. Drug discovery and development is a significant application segment as reporter gene assays are widely used in screening compounds and evaluating their effects. Gene regulation studies involve the analysis of gene expression, transcription, and translation processes. Protein-protein interaction studies utilize reporter gene assays to investigate how proteins interact within cells. Promoter analysis segment focuses on the study of gene promoters and their regulation.

- **By End User**: End users of reporter gene assays include pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and others. Pharmaceutical and biotechnology companies are the primary users of reporter gene assays, employing them in various stages of drug discovery and development. Academic and research institutes utilize these assays for fundamental research and studies. CROs offer assay services to pharma companies and research institutions, driving the usage of reporter gene assays in outsourced projects.

**Market Players**

- **Promega Corporation**: Promega Corporation is a prominent player in the reporter gene assay market, offering a wide range of assay kits, reagents, and instruments. The company is known for its high-quality products and innovative solutions in gene expression analysis.

- **Thermo Fisher Scientific, Inc.**: Thermo Fisher Scientific is a leading provider of reporter gene assay products, including cell lines, rePromega Corporation and Thermo Fisher Scientific, Inc. are key market players in the reporter gene assay market, each contributing significantly to the growth and development of this sector. Promega Corporation is renowned for its extensive range of assay kits, reagents, and instruments tailored for gene expression analysis. The company's commitment to delivering high-quality products and innovative solutions has solidified its position in the market. Its diverse product portfolio caters to the varying needs of researchers and pharmaceutical companies engaged in drug discovery and development and gene regulation studies. Promega Corporation's emphasis on technological advancements and customer-centric approach further enhances its competitive edge in the reporter gene assay market.

Thermo Fisher Scientific, Inc. stands out as a leading provider of reporter gene assay products, including cell lines, reagents, and instruments that are essential for conducting accurate and reliable gene expression analyses. The company's comprehensive offerings in this segment cater to a broad spectrum of applications, including drug discovery, gene regulation studies, and protein-protein interaction analysis. Thermo Fisher Scientific's focus on research and development has resulted in the introduction of cutting-edge solutions that enable researchers to gain deeper insights into gene expression dynamics. The company's commitment to innovation, coupled with its strong market presence and global distribution network, positions it as a key player driving the growth of the reporter gene assay market.

In terms of market dynamics, the reporter gene assay market is experiencing steady growth driven by the increasing demand for advanced tools and technologies for gene expression analysis. The rise in research activities in areas such as drug discovery, gene regulation, and protein-protein interaction studies further fuels the adoption of reporter gene assays across different end-user segments. Pharmaceutical and biotechnology companies remain the primary users of reporter gene assays, leveraging these tools to streamline their drug development pipelines and enhance target identification and validation processes. Academic and research institutes also play a crucial role in driving market growth, as they rely on reporter gene assays for fundamental research and elucidating gene regulatory mechanisms.

The emergence of contract research organizations (C**Global Reporter Gene Assay Market, By Product (Assay Kits and Reagents), Application (Promoter Structural and Functional Analysis, Cell Signaling Pathways, Protein Interaction, In Vitro Studies, Clinical and Gene Regulation), Application (Gene Regulation, Protein Interaction, Cell Signalling Pathways), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, CROs) – Industry Trends and Forecast to 2029.**

The global reporter gene assay market is witnessing significant growth attributed to the escalating demand for advanced tools for gene expression analysis. The market segmentation based on product type includes assay kits, reagents, cell lines, and instruments. Assay kits play a crucial role in facilitating the analysis by providing all necessary components, while reagents are essential for the execution of assays. Cell lines are pivotal for gene expression studies, and instruments such as luminometers and microplate readers are required for detection and analysis purposes. In terms of applications, the market can be segmented into drug discovery and development, gene regulation studies, protein-protein interaction, and promoter analysis. Drug discovery is a key application for reporter gene assays, aiding in compound screening and evaluation. Gene regulation studies involve the analysis of gene expression mechanisms, while protein-protein interaction studies focus on understanding cellular protein interactions. The promoter analysis segment is dedicated to studying gene promoters and their regulation.

End users of reporter gene assays encompass pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Reporter Gene Assay Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Reporter Gene Assay Market.

Global Reporter Gene Assay Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.

The following are the regions covered in this report.

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

This study answers to the below key questions:

What are the key factors driving the Reporter Gene Assay Market?

What are the challenges to market growth?

Who are the key players in the Reporter Gene Assay Market?

What are the market opportunities and threats faced by the key players?

Browse Trending Reports:

Air Sports Equipment Market Secondary Macronutrients Market Blood Gas Analyzer Market Methotrexate Injection Market Smart Room Heater Market Battery Market Infrastructure As a Service Iaas Health Cloud Market Peritonitis Treatment Market Yacht Charter Market Next Generation Printing Ink Market Functional Confectionery Market Herbal Ready To Brink Beverages Market Wirewound Resistor Market Gelatin Substitutes Market Soy Based Surfactants Market Trimethlyaminuria Market Secondary Agricultural Nutrients Market Tomatoes Market Electric Kick Scooters Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[spookysaladchaos]

Global Top 32 Companies Accounted for 58% of total COVID-19 Rapid Antigen Test Kits market (QYResearch, 2021)

The COVID-19 Rapid Antigen Test Kit is an in-vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 viral nucleoprotein antigens in Fluorescence Immunochromatography, Colloidal Gold Immunochromatography and Latex Immunochromatography specimens from individuals suspected of COVID-19 by their healthcare provider.

According to the new market research report “Global COVID-19 Rapid Antigen Test Kits Market Report 2023-2029”, published by QYResearch, the global COVID-19 Rapid Antigen Test Kits market size is projected to reach USD 12.5 billion by 2029, at a CAGR of -6.8% during the forecast period.

Figure.   Global COVID-19 Rapid Antigen Test Kits Market Size (US$ Million), 2018-2029

Above data is based on report from QYResearch: Global COVID-19 Rapid Antigen Test Kits Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch..

Figure.   Global COVID-19 Rapid Antigen Test Kits Top 32 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated)

Above data is based on report from QYResearch: Global COVID-19 Rapid Antigen Test Kits Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.

The global key manufacturers of COVID-19 Rapid Antigen Test Kits include Abbott, ROCHE, SD Biosensor, Orient Gene, BD, Quidel, Beijing Hotgen Biotech, ACON Biotech, Celltrion, Jinwofu Bioengineering Technology, etc. In 2021, the global top 10 players had a share approximately 58.0% in terms of revenue.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

[pavanpj]

Immunoassay Revolution: Understanding Market Size, Share, and Trends

 The global immunoassay market is experiencing robust growth, driven by the increasing prevalence of chronic diseases, advancements in technology, and a growing emphasis on early disease detection. As of 2023, immunoassays, which encompass a diverse range of diagnostic techniques, play a pivotal role in the detection and quantification of various analytes, including proteins, hormones, and biomarkers. These assays find extensive application in clinical diagnostics, pharmaceutical research, and food testing, contributing to the overall improvement of healthcare and life sciences.

Over the projection period of 2022–2032, the global immunoassay market is expected to increase at a 6% compound annual growth rate (CAGR) and reach a market size of US$ 53 billion. With a 5.7% year-over-year growth rate, the market, estimated at US$ 28 billion in 2021, is expected to expand to US$ 29.6 billion in 2022.

Download a Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4766?PJ 

Competitive Landscape

The key players are taking on extensive initiatives to address the unmet needs of patients in the domain of immunoassays and stressing more on new product development, mergers and acquisitions, and regional expansion.

Molecular biology subsidiary BioFire Diagnostics, a subsidiary of BioMérieux SA, filed an application with the Food and Drug Administration in January 2020 for clearance of its BIOFIRE Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE BCID2 Panel has an expanded list of antibiotic resistance genes, considerably more pathogens, and several revised targets compared to the previous BIOFIRE BCID Panel.

Siemens Healthineers announced in November 2020 that its SARS-CoV-2 IgG Antibody Test has been certified as a CE mark measurement of neutralizing antibodies. The test is an improved version of the COVID-19 antibody test it previously launched.

Maglumi HIV Ab/Ag Combi CLIA kit, Snibe Diagnostics’ fourth-generation chemiluminescence immunoassay that can detect HIV-1 and HIV-2 antibodies as well as the HIV-1 p24 antigen, obtained CE marking in April 2021, allowing it to be sold in the European Union and other regions accepting the designation.

Key Companies Profiled

DiaSorin S.p.A.

Sysmex Corporation

bioMerieux SA

Ortho Clinical Diagnostics

Thermo Fisher Scientific Inc.

Becton

Dickinson and Company 

Merck KGaA.

Increased prevalence of infectious and chronic illnesses, such as COVID-19, is linked to market expansion. Further driving increase will be the ageing population, which is more prone to infectious and chronic illnesses.

Key Market Drivers:

Rising Disease Burden: The escalating burden of chronic diseases, such as cardiovascular disorders, cancer, and infectious diseases, is a primary driver for the immunoassay market. The need for accurate and timely diagnosis to initiate appropriate treatment regimens has spurred the demand for immunoassay-based diagnostic solutions.

Technological Advancements: Ongoing advancements in immunoassay technologies are enhancing the sensitivity, specificity, and speed of diagnostic tests. Automation, multiplexing, and the integration of novel detection platforms are improving the efficiency of immunoassays, making them invaluable tools in clinical laboratories and research settings.

Point-of-Care Testing (POCT): The growing trend towards decentralized testing and the demand for rapid diagnostic results have propelled the adoption of immunoassays in point-of-care settings. Portable immunoassay devices allow for quick on-site testing, enabling healthcare providers to make immediate clinical decisions and improve patient outcomes.

Challenges and Opportunities:

Complexity of Assay Development: The complexity associated with the development of immunoassays, including the selection of appropriate antibodies, assay optimization, and standardization, poses a challenge to market growth. However, overcoming these challenges presents opportunities for innovation and the creation of more sophisticated and reliable immunoassay platforms.

Competitive Landscape: The immunoassay market is highly competitive, with numerous players offering a wide array of products. To thrive in this landscape, companies are exploring niche markets, developing specialized assays, and engaging in strategic collaborations to expand their product portfolios and gain a competitive edge.

Current Industry Trends (2023):

Expansion of Biomarker Discovery: Immunoassays are integral in the discovery and validation of biomarkers for various diseases. The emphasis on precision medicine and personalized treatment approaches has fueled the expansion of biomarker research, driving the demand for immunoassay platforms capable of detecting specific biomolecules indicative of disease states.

Adoption of Multiplex Immunoassays: Multiplex immunoassays, allowing the simultaneous detection of multiple analytes in a single sample, are gaining prominence. These assays streamline the diagnostic process, conserve sample volumes, and provide a comprehensive understanding of the patient's health status. The adoption of multiplexing is particularly notable in cancer research and autoimmune disease diagnostics.

Integration of Artificial Intelligence (AI): The integration of artificial intelligence and machine learning in immunoassay data analysis is a growing trend. AI algorithms enhance the accuracy and speed of result interpretation, aiding healthcare professionals in making more informed decisions. This integration contributes to the evolving landscape of precision diagnostics.

Key Segments Covered in the Immunoassay Market Report

By Technology Type :

Chemiluminescence Immunoassay (CLIA)

Enzyme Linked Fluorescence Assay (ELFA)

Enzyme-linked Immunosorbent Assay (ELISA)

Radioimmunoassay (RIA)

Others

By Product :

Analyzer Immunoassay

Consumable Immunoassay

By Application :

Infectious Diseases

Orthopedics

Cardiology

Oncology

Endocrinology

Other Applications

By End-User :

Immunoassay for Blood Banks

Immunoassay for Hospitals & Diagnostic Laboratories

Immunoassay for Others (Pharmaceutical & Biotech Companies, Forensic Labs, Academic & Research Institutes, etc.)

By Region :

North America

Western Europe

Asia Pacific

Middle East & Africa

Eastern Europe

Latin America

Global Industry News (2023):

Rapid COVID-19 Diagnostics: The ongoing global response to the COVID-19 pandemic has highlighted the pivotal role of immunoassays in infectious disease diagnostics. Rapid immunoassay tests for detecting SARS-CoV-2 antigens and antibodies have been pivotal in mass testing efforts, emphasizing the adaptability and versatility of immunoassay technologies in addressing emerging health challenges.

Investments in Research and Development: Key players in the immunoassay market are actively investing in research and development to introduce novel assays with enhanced performance characteristics. This includes the development of ultrasensitive assays, novel biomarker panels, and innovative detection methodologies to meet the evolving needs of the healthcare and research communities.

Strategic Collaborations: Strategic collaborations and partnerships between diagnostic companies, pharmaceutical firms, and research institutions are prevalent in the immunoassay market. These collaborations aim to leverage collective expertise, access shared resources, and accelerate the development and commercialization of novel immunoassay-based diagnostics.

Focus on Sustainability: Sustainability is gaining traction in the immunoassay market, with a focus on developing eco-friendly assay components, reducing waste generation, and adopting green laboratory practices. This aligns with broader industry efforts to minimize environmental impact and promote sustainable healthcare solutions.

The immunoassay market continues to be a dynamic and vital component of the diagnostics and life sciences landscape. The ongoing convergence of technological advancements, the expansion of biomarker research, and the market's response to global health challenges underscore the adaptability and resilience of immunoassay technologies. As the industry navigates complexities and embraces opportunities for innovation, immunoassays are expected to play an increasingly integral role in shaping the future of diagnostics and healthcare.

[themarketinsights]

Somatic Genetic Testing Market to Witness Huge Growth by 2028

Latest released the research study on Global Somatic Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Somatic Genetic Testing Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Somatic Genetic Testing The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are ARUP Laboratories (United States), ASURAGEN Inc. (United States), Beijing Genomics Institute (BGI) Genomics Co., Ltd (China), bioMerieux S.A. (France), CENTOGENE N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health, Inc. (United States), Illumina, Inc. (United States), Invivoscribe, Inc. (United States),

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/176535-global-somatic-genetic-testing-market

Somatic Genetic Testing Market Definition:

The Global Increase in Cancer Prevalence will help to boost the global Somatic Genetic Testing market in the forecasted period. Somatic genetic tests look for gene changes only. Somatic testing is done on cancer cells. It can help doctors learn more about your cancer. Germline testing is done on non-cancer cells. It can show if a genetic change is in all of the cells in your body. Somatic testing is done on cancer cells. It can help doctors learn more about your cancer. Germline testing is done on non-cancer cells. It can show if a genetic change is in all of the cells in your body. Somatic mutation analysis is a standard of practice for tumors in order to identify therapeutic sensitizing and resistance mutations. This allows a finer assessment of the diagnosis and prognosis and targeted therapies directed towards the individual patient's tumor profile.

Market Trend:

Decreasing Cost of Sequencing

Increasing Adoption of Inorganic Growth Strategies

Market Drivers:

Global Increase in Cancer Prevalence

Increasing Consumer Awareness for Tailored Cancer Therapy

 

Market Opportunities:

Technological Advancements in the Field of Cancer Genomics

Massive Scope for Adoption of NGS-based Somatic Genetic Testing in the Emerging Markets

 

The Global Somatic Genetic Testing Market segments and Market Data Break Down are illuminated below:

by Type (Product (Kits and Assays, Instruments, and Software), Services), Application (Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Liver Cancer, Ovarian Cancer, and Other Solid Tumors), Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)), Technology (Sequencing (NGS and Traditional Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, Other Technologies), Sample (Tissue-Based, Blood-Based, Bone Marrow Aspirates, Others), End User (Academic and Research Institutions, Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/176535-global-somatic-genetic-testing-market

Strategic Points Covered in Table of Content of Global Somatic Genetic Testing Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Somatic Genetic Testing market

Chapter 2: Exclusive Summary – the basic information of the Somatic Genetic Testing Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Somatic Genetic Testing

Chapter 4: Presenting the Somatic Genetic Testing Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Somatic Genetic Testing market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2021-2026).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Somatic Genetic Testing Market is a valuable source of guidance for individuals and companies in decision framework.

Data Sources & Methodology The primary sources involves the industry experts from the Global Somatic Genetic Testing Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/176535-global-somatic-genetic-testing-market

What benefits does AMA research study is going to provide?

Latest industry influencing trends and development scenario

Open up New Markets

To Seize powerful market opportunities

Key decision in planning and to further expand market share

Identify Key Business Segments, Market proposition & Gap Analysis

Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

Contact Us:

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837

[industrynewsupdates]

Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Oligonucleotide Synthesis Market Segmentation

Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:

Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Oligonucleotides

o DNA

o Column-based

o Array-based

o RNA

o By Technology

o Column-based

o Array-based

o By Type

o Short RNA Oligos (<65 nt)

o Long RNA Oligos (>65 nt)

o CRISPR (sgRNA)

• Equipment/Synthesizer

• Reagents

• Services

o DNA

o Custom Oligo Synthesis Services

o 25 nmol

o 50 nmol

o 200 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

o RNA

o Custom Oligo Synthesis Services

o 25 nmol

o 100 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

Application Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Primers

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• PCR Assays & Panels

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Sequencing

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• DNA Microarrays

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Fluorescence In Situ Hybridization (FISH)

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Antisense Oligonucleotides

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Other Applications

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Spain

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Dharmacon Inc.

• Agilent Technologies

• Bio-synthesis

• Kaneka Eurogentec S.A

• LGC Biosearch Technologies

• Biolegio

• Twist Bioscience

Recent Developments

• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[reportprimerahul]

Loop-mediated Isothermal Amplification (LAMP) Kit Market Size, Type, segmentation, growth and forecast 2023-2030

Loop-mediated Isothermal Amplification (LAMP) Kit Market

The Loop-mediated Isothermal Amplification (LAMP) Kit Market is expected to grow from USD 93.00 Million in 2022 to USD 164.00 Million by 2030, at a CAGR of 8.40% during the forecast period.

Loop-mediated Isothermal Amplification (LAMP) Kit Market Size

The Loop-mediated Isothermal Amplification (LAMP) Kit is a tool used for the detection and amplification of DNA or RNA segments in various applications such as medical diagnostics, agriculture, and scientific research. The market for LAMP kits is segmented based on type, application, and region, with market players including Eiken Chemical, HiberGene Diagnostic, Nippon Gene, Mast Group, New England Biolabs, Optigene, and Lucigen Corporation. Regulatory and legal factors specific to market conditions are also considered, ensuring compliance with regional laws and standards. The market is expected to see growth due to the increasing demand for accurate and fast diagnosis in medical and agriculture industries. The Asia Pacific region is expected to have the highest market share due to the presence of major market players and a growing need for efficient diagnostic tools.

Loop-mediated Isothermal Amplification (LAMP) Kit Market Key Player

Eiken Chemical

HiberGene Diagnostic

Nippon Gene

Mast Group

New England Biolabs

Buy Now & Get Exclusive Discount on this https://www.reportprime.com/enquiry/request-discount/11105

Loop-mediated Isothermal Amplification (LAMP) Kit Market Segment Analysis

The Loop-mediated Isothermal Amplification (LAMP) Kit target market is primarily composed of molecular biology and genetics researchers, medical laboratories, veterinary clinics, and drug discovery companies. This technology is widely used in diagnosing infectious diseases, such as HIV, tuberculosis, malaria, and influenza. Moreover, LAMP is used in food safety testing, plant pathology, environmental monitoring, and forensic science. Recently, with the COVID-19 pandemic, there has been a surge in demand for LAMP diagnostics due to its high sensitivity, specificity, and portability.

The major factors driving revenue growth of the Loop-mediated Isothermal Amplification (LAMP) Kit market are increasing prevalence of infectious diseases, rising demand for rapid and accurate diagnostics, technological advancements in LAMP technology, and growing awareness among end-users. Moreover, the ease of use, cost-effectiveness, and user-friendliness of LAMP kits compared to traditional PCR and ELISA-based assays are also contributing to the market growth.

The latest trends followed by Loop-mediated Isothermal Amplification (LAMP) Kit market include the development of automated LAMP platforms, the integration of LAMP technology with microfluidics, and the incorporation of LAMP into point-of-care devices. Additionally, there is a growing trend towards the use of LAMP in field-based and resource-limited settings due to its suitability for use in low-resource settings.

The major challenges faced by the Loop-mediated Isothermal Amplification (LAMP) Kit market are the lack of standardization in LAMP protocols, the need for robust quality control measures, and the limited availability of LAMP assays for specific pathogens. Moreover, there is a need for regulatory approval of LAMP assays, which could lengthen the approval process and increase the cost of LAMP kits.

The main findings of the report highlight the rapid growth of the LAMP market, the increasing adoption of LAMP in various industries, and technological advancements in LAMP technology such as automation, miniaturization, and integration with microfluidics. The report's recommendations include the need for standardization of LAMP protocols, the establishment of quality control measures, the development of more specific and sensitive LAMP assays, and the need for regulatory approval of LAMP assays.

Overall, the Loop-mediated Isothermal Amplification (LAMP) Kit market is expected to continue to grow rapidly owing to its numerous advantages over traditional diagnostic methods. The increasing demand for rapid and accurate diagnostics, especially in the context of emerging infectious diseases, is expected to drive the market growth in the coming years. However, the challenges of standardization and quality control must be taken seriously to ensure the reproducibility and reliability of LAMP assays.

This report covers impact on COVID-19 and Russia-Ukraine wars in detail.

Purchase This Report: https://www.reportprime.com/checkout?id=11105&price=3590

Market Segmentation (by Application):

Medical Diagnostic

Agriculture

Scientific Research

Information is sourced from www.reportprime.com

[market-insider]

Biomarkers in Personalized Medicine: A Comprehensive Market Study

The global personalized medicine biomarkers market size is expected to reach USD 43.07 billion by 2030. The growth is attributed to the rising awareness, importance of predicting prognosis, and selection of dose. Moreover, personalized medicine biomarkers serve as an essential tool for the selection of patients and providing the right treatment to the right patient further propelling the demand for personalized medicine biomarkers.

Gain deeper insights on the market and receive your free copy with TOC now @: Personalized Medicine Biomarkers Market Report

Biomarkers are unique analytes that can be utilized to improve diagnosis forecast treatment outcomes and direct treatment decisions. They are crucial to personalized medicine. The increased usage of biomarkers to enhance patient outcomes is popular in clinical trials, and its use in clinical practice is expanding quickly. The development of personalized medicines using biomarkers is expected to create effective and safe therapies for every patient. This is a major relief for patients at advanced stages of chronic diseases like cancer, which further drives the market growth. For instance, in August 2022, VENTANA MMR RxDx Panel, an FDA approved first IHC-based assay used for the identification of patients with advanced cancer that is Pembrolizumab treatment eligible.

Early detection/screening biomarkers predict the outcome of disease in patient population prior to therapy. It can also help enrich clinical trials by helping choose patients more likely to respond to treatment. For instance, Oncotype Dx is a diagnostic test developed by Genomic Health, Inc. This test examines 21 genes and helps predict the likelihood of reoccurrence of breast cancer in a patient after initial treatment. In April 2022, updated ASCO guidelines recommended the usage of the Oncotype DX test for breast cancer patients at early stages to guide treatment decisions.

Moreover, biomarkers are used for their predictive and prognostic utility that helps predict the occurrence of a health condition. For instance, the prostate-specific antigen is used to predict the survival of patients with prostate cancer. CRP is used to predict disease-free survival in breast cancer and as a risk factor in cardiovascular disorders. Serum LDH helps predict survival in case of metastatic brain tumors. Similarly, CA125 helps predict metastatic diseases in patients with uterine carcinoma.

Furthermore, key players operating in the personalized medicine biomarkers industry are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in October 2021, Agilent Technologies Inc. received FDA approval for Agilent Ki-67 IHC MIB-1 pharmDx (Dako Omnis), for the identification of patients with a high risk of breast cancer recurrence.